📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. (2019)

First Author: Hanna MG

Attributed to: MICA: MRC Centre for Neuromuscular Diseases funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(19)30200-5

PubMed Identifier: 31397289

Publication URI: http://europepmc.org/abstract/MED/31397289

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Neurology

Issue: 9

ISSN: 1474-4422